Kay Melancon
Gerontology · Lafayette, LANPI 1598413049
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,063 and has fallen 76.5% since, to $249 in 2025.
Across 96 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$594
- Abiomed$523
- Boston Scientific$173
- Edwards Lifesciences$140
- Cardiovascular Systems Inc.$137
- Astellas Pharma US Inc$119
- plus $970 from 18 others
What the payments were for
- Food & beverage$2,655100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $594 |
| Abiomed | 14 | $523 |
| Boston Scientific | 7 | $173 |
| Edwards Lifesciences | 1 | $140 |
| Cardiovascular Systems Inc. | 4 | $137 |
| Astellas Pharma US Inc | 1 | $119 |
| Abbott | 1 | $119 |
| Johnson & Johnson | 6 | $112 |
| Pfizer | 4 | $83 |
| Alnylam Pharmaceuticals Inc. | 3 | $71 |
| Novartis | 4 | $68 |
| Merck | 4 | $65 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $62 |
| Silk Road Medical, Inc. | 1 | $59 |
| Philips North America LLC | 3 | $55 |
| Boehringer Ingelheim | 3 | $50 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Kestra Medical Technology Services, Inc. | 1 | $37 |
| AstraZeneca | 2 | $32 |
| Bayer | 2 | $32 |
| Novo Nordisk | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Itamar Medical Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$143
- LEXISCAN$119
- CARDIOMEMS$119
- LifeVest$100
How this compares
$2,655 in reported general payments places this provider in the 80th percentile of 64 gerontology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $26,281 |
| BrilintaTicagrelor | 28 | $12,887 |
| EntrestoSacubitril/Valsartan | 14 | $9,374 |
| JardianceEmpagliflozin | 11 | $6,573 |
| ClopidogrelClopidogrel Bisulfate | 134 | $972 |
| Atorvastatin Calcium | 62 | $445 |
| Amiodarone Hcl | 24 | $235 |
| Carvedilol | 17 | $167 |
| Metoprolol Succinate | 26 | $137 |
| Furosemide | 37 | $122 |
| Metoprolol Tartrate | 22 | $120 |
| Amlodipine Besylate | 20 | $43 |
| Doxycycline Hyclate | 12 | $42 |
| Pantoprazole Sodium | 11 | $37 |
| Benazepril Hcl | 13 | $9 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $26,28148 claims |
| AstraZenecaBrilinta | $32 | $12,88728 claims |
| NovartisEntresto | $68 | $9,37414 claims |
| Boehringer IngelheimJardiance | $50 | $6,57311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 gerontology providers in Louisiana.
Other gerontology in Lafayette
- Brandt SandersLafayette$3K
- Icela WilliamsLafayette$2K
- Bobbi DerasLafayette$878
- Kristyn WunderLafayette$485
- Christopher DuhonLafayette$317
- Christopher VincentLafayette$50
- Jodie HarrisonSlidell$12K
- Whitney StevensSlidell$10K
- Rebekah HendryBossier City$6K
- Jessica GaubertBaton Rouge$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.